Overview

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

Status:
Completed

Trial end date:
2016-02-08

Target enrollment:

Participant gender:

Summary

Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Budesonide, Formoterol Fumarate Drug Combination
Formoterol Fumarate